• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by United Therapeutics Corporation

    6/2/26 5:07:07 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UTHR alert in real time by email
    SD 1 tm2616715d1_sd.htm FORM SD

     

     

      

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM SD

     

    SPECIALIZED DISCLOSURE REPORT

     

    United Therapeutics Corporation

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware   000-26301   52-1984749
    (State or Other   (Commission   (I.R.S. Employer
    Jurisdiction of   File Number)   Identification Number)
    Incorporation or Organization)        

     

    1000 Spring Street    
    Silver Spring, MD   20910
    (Address of Principal Executive Offices)   (Zip Code)

     

    James Edgemond, (301) 608-9292

    (Name and telephone number, including area code, of the

    person to contact in connection with this report)

     

    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

     

    x

    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2025.

     

    ¨Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended ______.

     

     

      

     

     

      

    Item 1.01  Conflict Minerals Disclosure and Report.

     

    United Therapeutics Corporation (UT) is committed to social responsibility in the supply chain of its materials, including considerations and requirements relating to the environment, safety, health, and human rights. This includes efforts to comply with rules and regulations promulgated by the U.S. Securities and Exchange Commission to implement Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act (the Conflict Mineral Rules). These rules require UT to conduct a reasonable country of origin inquiry that is reasonably designed to determine whether Conflict Minerals (defined below) necessary to the functionality or production of products manufactured or contracted to be manufactured by UT originated in Covered Countries (defined below) or came from recycled or scrap sources.

     

    The Conflict Mineral Rules define Conflict Minerals as cassiterite, columbite-tantalite, gold, wolframite, and their derivatives (which are limited to tin, tantalum, and tungsten). Covered Countries is defined as the Democratic Republic of the Congo and its adjoining countries.

     

    In accordance with the Conflict Mineral Rules, UT has determined that it has two products that contain Conflict Minerals (the Relevant Products). UT has conducted a good faith, reasonable country of origin inquiry (as described below) and determined that certain Conflict Minerals in the Relevant Products may have originated in Covered Countries. However, based on supplier responses and due diligence, UT has no reason to believe that such Conflict Minerals were sourced from smelters or refiners that are not compliant with the Responsible Minerals Initiative (RMI) or equivalent industry standards. Therefore, UT is not required to provide a conflict minerals report concerning the Relevant Products.

     

    UT contracts to manufacture the Relevant Products and does not directly purchase Conflict Minerals included in the products. UT’s reasonable country of origin inquiry included an examination of the bill of materials and approved supplier list for the Relevant Products. Based on that review, UT conducted a comprehensive inquiry of a total of 100 companies, representing all UT’s direct suppliers relating to the Relevant Products and their respective first and second-tier component suppliers. UT requested each supplier to provide a written statement regarding its use of Conflict Minerals to determine whether any Conflict Minerals originating in Covered Countries (and not from scrap or recycled sources) were incorporated into the Relevant Products. UT received responses from all of these suppliers, and, based on their responses, had no reason to believe Conflict Minerals necessary to the functionality or production of the Relevant Products were sourced from smelters or refiners that are non-compliant with the RMI.

     

    Conflict Minerals Disclosure

     

    This Conflict Minerals Disclosure is publicly available on UT’s website, located at http://ir.unither.com/corporate-governance.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

     

      UNITED THERAPEUTICS CORPORATION
         
    Date: June 2, 2026 By: /s/ John S. Hess, Jr.
      Name: John S. Hess, Jr.
      Title: EVP, Deputy General Counsel

     

     

    Get the next $UTHR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UTHR

    DatePrice TargetRatingAnalyst
    5/7/2026$735.00Equal Weight → Overweight
    Wells Fargo
    4/10/2026$700.00Outperform
    Raymond James
    10/20/2025$414.00Underweight
    Wells Fargo
    9/26/2025$569.00Outperform
    RBC Capital Mkts
    6/2/2025$405.00Overweight
    Cantor Fitzgerald
    4/25/2025Overweight → Equal Weight
    Wells Fargo
    4/21/2025$314.00Underperform → Neutral
    BofA Securities
    7/11/2024$310.00 → $321.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $UTHR
    SEC Filings

    View All

    SEC Form SD filed by United Therapeutics Corporation

    SD - UNITED THERAPEUTICS Corp (0001082554) (Filer)

    6/2/26 5:07:07 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - UNITED THERAPEUTICS Corp (0001082554) (Filer)

    5/6/26 6:31:29 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by United Therapeutics Corporation

    10-Q - UNITED THERAPEUTICS Corp (0001082554) (Filer)

    5/6/26 6:30:51 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UTHR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference

    United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide a company overview and update on Wednesday, June 3, 2026, from 12:45 to 1:15 p.m. EST, at the Jefferies Global Healthcare Conference in New York. The presentation can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 90 days. About United Therapeutics Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pu

    5/27/26 7:00:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026

    The pivotal TETON-1 phase 3 study of nebulized Tyvaso® (treprostinil) Inhalation Solution in idiopathic pulmonary fibrosis (IPF) preserved lung function as measured by absolute forced vital capacity (FVC) and demonstrated reduced risk of a clinical worsening event, meeting both its primary endpoint and a key secondary endpoint with statistical significance, respectively In combined analyses of TETON-1 and TETON-2 — also included in the NEJM publication and presented at ATS — nebulized Tyvaso achieved statistically significant treatment effects across the primary and most secondary efficacy endpoints Nebulized Tyvaso combines direct lung delivery with multi-modal activity across fibrotic

    5/18/26 4:15:00 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026

    The long-term, pivotal, phase 3 ADVANCE OUTCOMES study met its primary endpoint, with ralinepag achieving a statistically significant 55% reduction in risk of clinical worsening in predominantly pre-treated patients with pulmonary arterial hypertension (PAH) Ralinepag achieved statistical significance for important secondary endpoints, reducing levels of N-terminal pro-B-type natriuretic peptide, a critical biomarker for heart failure, and improving exercise capacity Investigational ralinepag combines potent receptor binding affinity with continuous exposure to deliver long-term, durable efficacy, and disease-mitigating outcomes, and is expected to become the first and only once-daily o

    5/17/26 2:15:00 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UTHR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairperson & CEO Rothblatt Martine A exercised 9,500 shares at a strike of $146.03 and sold $4,579,018 worth of shares (8,000 units at $572.38) as part of a pre-agreed trading plan (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    5/27/26 4:30:25 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UTHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairperson & CEO Rothblatt Martine A exercised 9,500 shares at a strike of $146.03 and sold $5,190,128 worth of shares (9,500 units at $546.33) as part of a pre-agreed trading plan (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    6/5/26 4:31:11 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO AND TREASURER Edgemond James exercised 10,000 shares at a strike of $117.76 and sold $5,462,824 worth of shares (10,000 units at $546.28) as part of a pre-agreed trading plan (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    6/5/26 4:31:30 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & GENERAL COUNSEL Mahon Paul A exercised 8,300 shares at a strike of $146.03 and sold $4,540,642 worth of shares (8,300 units at $547.07) as part of a pre-agreed trading plan (SEC Form 4)

    4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)

    6/4/26 5:30:37 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UTHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    United Therapeutics upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded United Therapeutics from Equal Weight to Overweight and set a new price target of $735.00

    5/7/26 8:00:38 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on United Therapeutics with a new price target

    Raymond James initiated coverage of United Therapeutics with a rating of Outperform and set a new price target of $700.00

    4/10/26 8:35:42 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on United Therapeutics with a new price target

    Wells Fargo initiated coverage of United Therapeutics with a rating of Underweight and set a new price target of $414.00

    10/20/25 8:04:30 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UTHR
    Financials

    Live finance-specific insights

    View All

    United Therapeutics Corporation Reports First Quarter 2026 Financial Results

    United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2026. Total revenues in the first quarter of 2026 decreased by two percent year-over-year to $781.5 million, compared to $794.4 million in the first quarter of 2025. "In the first quarter of 2026, we extended our run of clinical success, with positive results from both our ADVANCE OUTCOMES and TETON-1 studies," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "These readouts have the potential to meaningfully expand the breadth of our future growth and support further revenue diversification while

    5/6/26 6:30:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026

    United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2026 financial results in a press release that will be issued on Wednesday, May 6, 2026 at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast on Wednesday, May 6, 2026, at 9:00 a.m. Eastern Time that will be accessible at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. About United Therapeutics Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics tran

    4/22/26 7:00:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results

    United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2025. Full year 2025 revenues rose to a record $3.18 billion, reflecting 11% growth over 2024. "As we close out another remarkable year with record total revenue for the fourth year in a row, I extend my thanks to our Unitherians whose unwavering commitment to innovation and excellence fuels our mission," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "Looking ahead, our ADVANCE OUTCOMES and TETON-1 clinical programs are on the cusp of unveiling pivotal data that could unlock signific

    2/25/26 6:30:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UTHR
    Leadership Updates

    Live Leadership Updates

    View All

    United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors

    United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors appointed Kevin J. Tracey, M.D., to its Board on January 21, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122174254/en/Kevin Tracey was recently elected to United Therapeutics' Board of Directors. Dr. Tracey is President, CEO, and the Karches Family Distinguished Chair in Medical Research at The Feinstein Institutes for Medical Research. He is a Professor of Molecular Medicine and Neurosurgery at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and Executive Vice Pres

    1/22/26 7:00:00 AM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IM Therapeutics Announces Appointment of Jonathan Rigby to Board of Directors

    WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen (HLA) variants known to play a strong role in autoimmune diseases. The Company’s lead drug candidate, IMT-002, is in Phase 1b clinical trials in type 1 diabetes (T1D). Patients in the study were preselected for HLA-DQ8, the

    1/27/21 8:00:00 AM ET
    $CLGN
    $UTHR
    $XERS
    Industrial Specialties
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $UTHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by United Therapeutics Corporation

    SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    11/8/24 4:30:29 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by United Therapeutics Corporation

    SC 13G - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    10/16/24 1:03:48 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by United Therapeutics Corporation (Amendment)

    SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)

    6/10/24 12:15:17 PM ET
    $UTHR
    Biotechnology: Pharmaceutical Preparations
    Health Care